Chemical: Drug
irbesartan

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.



PharmGKB contains no Clinical Variants that meet the highest level of criteria.

To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the page.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page.

Links in the "Gene" column lead to PharmGKB Gene Pages.

List of all variant annotations for irbesartan

Gene ? Variant?
(147)
Alternate Names ? Chemicals ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
No VIP available CA VA
rs1057910 NC_000010.10:g.96741053A=, NC_000010.10:g.96741053A>C, NC_000010.11:g.94981296A=, NC_000010.11:g.94981296A>C, NG_008385.1:g.47639A=, NG_008385.1:g.47639A>C, NM_000771.3:c.1075A=, NM_000771.3:c.1075A>C, NP_000762.2:p.Ile359=, NP_000762.2:p.Ile359Leu, XM_005269575.1:c.1075A=, XM_005269575.1:c.1075A>C, XP_005269632.1:p.Ile359=, XP_005269632.1:p.Ile359Leu, rs17847042, rs3198471, rs61212474
A > C
SNP
I359L
No VIP available No Clinical Annotations available VA
rs1137617 NC_000007.13:g.150648198A>G, NC_000007.13:g.150648198A>T, NC_000007.14:g.150951110A>G, NC_000007.14:g.150951110A>T, NG_008916.1:g.31817T>A, NG_008916.1:g.31817T>C, NM_000238.3:c.1956T>A, NM_000238.3:c.1956T>C, NM_001204798.1:c.936T>A, NM_001204798.1:c.936T>C, NM_172056.2:c.1956T>A, NM_172056.2:c.1956T>C, NM_172057.2:c.936T>A, NM_172057.2:c.936T>C, NP_000229.1:p.Tyr652=, NP_000229.1:p.Tyr652Ter, NP_001191727.1:p.Tyr312=, NP_001191727.1:p.Tyr312Ter, NP_742053.1:p.Tyr652=, NP_742053.1:p.Tyr652Ter, NP_742054.1:p.Tyr312=, NP_742054.1:p.Tyr312Ter, XM_011516185.1:c.1656T>A, XM_011516185.1:c.1656T>C, XM_011516186.1:c.1956T>A, XM_011516186.1:c.1956T>C, XP_011514487.1:p.Tyr552=, XP_011514487.1:p.Tyr552Ter, XP_011514488.1:p.Tyr652=, XP_011514488.1:p.Tyr652Ter, rs10226664, rs11538712, rs118033979, rs17221791, rs17424631, rs1805122, rs2228161, rs3201408, rs59788464, rs8179010
A > G
SNP
Y652Y
No VIP available CA VA
rs1367117 NC_000002.11:g.21263900G>A, NC_000002.12:g.21041028G>A, NG_011793.1:g.8046C>T, NM_000384.2:c.293C>T, NP_000375.2:p.Thr98Ile, XM_011532809.1:c.293C>T, XP_011531111.1:p.Thr98Ile, rs117604440, rs17246849, rs57336814
G > A
SNP
T98I
rs1799752 NC_000017.10:g.61565890_61565891insATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC, NC_000017.10:g.61565890_61565891insG, NC_000017.11:g.63488529_63488530insATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC, NC_000017.11:g.63488529_63488530insG, NG_011648.1:g.16457_16458insATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC, NG_011648.1:g.16457_16458insG, NM_000789.3:c.2306-119_2306-118insATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC, NM_000789.3:c.2306-119_2306-118insG, NM_001178057.1:c.584-119_584-118insATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC, NM_001178057.1:c.584-119_584-118insG, NM_152830.2:c.584-119_584-118insATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC, NM_152830.2:c.584-119_584-118insG, XM_005257110.1:c.1757-119_1757-118insATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC, XM_005257110.1:c.1757-119_1757-118insG, XM_006721737.2:c.644-119_644-118insATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC, XM_006721737.2:c.644-119_644-118insG
- > ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC
- > G
indel
No VIP available CA VA
rs1799853 NC_000010.10:g.96702047C=, NC_000010.10:g.96702047C>T, NC_000010.11:g.94942290C=, NC_000010.11:g.94942290C>T, NG_008385.1:g.8633C=, NG_008385.1:g.8633C>T, NM_000771.3:c.430C=, NM_000771.3:c.430C>T, NP_000762.2:p.Arg144=, NP_000762.2:p.Arg144Cys, XM_005269575.1:c.430C=, XM_005269575.1:c.430C>T, XP_005269632.1:p.Arg144=, XP_005269632.1:p.Arg144Cys, rs17110268, rs28371674, rs33968134, rs60690363
C > T
SNP
R144C
No VIP available No Clinical Annotations available VA
rs1799998 NC_000008.10:g.143999600A=, NC_000008.10:g.143999600A>G, NC_000008.11:g.142918184A=, NC_000008.11:g.142918184A>G, NG_008374.1:g.4660T=, NG_008374.1:g.4660T>C, NM_000498.3:c.-344T=, NM_000498.3:c.-344T>C, XM_011516877.1:c.-344T=, XM_011516877.1:c.-344T>C, XM_011516878.1:c.-344T=, XM_011516878.1:c.-344T>C, XM_011516879.1:c.-344T=, XM_011516879.1:c.-344T>C, XR_928729.1:n.-1946A=, XR_928729.1:n.-1946A>G, rs17777877, rs60977059
A > G
SNP
No VIP available CA VA
rs1801701 NC_000002.11:g.21228827C>T, NC_000002.12:g.21005955C>T, NG_011793.1:g.43119G>A, NM_000384.2:c.10913G>A, NP_000375.2:p.Arg3638Gln, XM_011532809.1:c.5869+4778G>A, rs17247291, rs386545637, rs52810909, rs57671111
C > T
SNP
R3638Q
No VIP available No Clinical Annotations available VA
rs4331 NC_000017.10:g.61564052A>G, NC_000017.11:g.63486691A>G, NG_011648.1:g.14619A>G, NM_000789.3:c.2193A>G, NM_001178057.1:c.471A>G, NM_152830.2:c.471A>G, NP_000780.1:p.Ala731=, NP_001171528.1:p.Ala157=, NP_690043.1:p.Ala157=, XM_005257110.1:c.1644A>G, XM_006721737.2:c.531A>G, XP_005257167.1:p.Ala548=, XP_006721800.2:p.Ala177=, rs17230334, rs17403344, rs17853604, rs2229837, rs3730030, rs386592477, rs4973, rs57496360
A > G
SNP
A731A
No VIP available No Clinical Annotations available VA
rs4762 NC_000001.10:g.230845977G>A, NC_000001.11:g.230710231G>A, NG_008836.1:g.9360C>T, NM_000029.3:c.620C>T, NP_000020.1:p.Thr207Met, rs16852387, rs3182294, rs52830531, rs60395225
G > A
SNP
T207M
No VIP available No Clinical Annotations available VA
rs5050 NC_000001.10:g.230849886T>G, NC_000001.11:g.230714140T>G, NG_008836.1:g.5451A>C, NM_000029.3:c.-58A>C, rs36218430, rs56809081
T > G
SNP
No VIP available No Clinical Annotations available VA
rs5051 NC_000001.10:g.230849872C>T, NC_000001.11:g.230714126C>T, NG_008836.1:g.5465G>A, NM_000029.3:c.-44G>A, rs16852405, rs36218427, rs3789681, rs60366145
C > T
SNP
No VIP available No Clinical Annotations available VA
rs5186 NC_000003.11:g.148459988A>C, NC_000003.12:g.148742201A>C, NG_008468.1:g.49331A>C, NM_000685.4:c.*86A>C, NM_004835.4:c.*86A>C, NM_009585.3:c.*86A>C, NM_031850.3:c.*86A>C, NM_032049.3:c.*86A>C, rs17231380, rs3192044, rs3732563, rs386597902, rs59796105
A > C
SNP
No VIP available CA VA
rs5370 NC_000006.11:g.12296255G>T, NC_000006.12:g.12296022G>T, NG_016196.1:g.10727G>T, NM_001168319.1:c.591G>T, NM_001955.4:c.594G>T, NP_001161791.1:p.Lys197Asn, NP_001946.3:p.Lys198Asn, XM_011514330.1:c.594G>T, XM_011514331.1:c.594G>T, XM_011514332.1:c.591G>T, XP_011512632.1:p.Lys198Asn, XP_011512633.1:p.Lys198Asn, XP_011512634.1:p.Lys197Asn, XR_241977.1:n.971C>A, rs17845238, rs17858054, rs2229566, rs57072783
G > T
SNP
K197N
No VIP available CA VA
rs699 NC_000001.10:g.230845794A>G, NC_000001.11:g.230710048A>G, NG_008836.1:g.9543T>C, NM_000029.3:c.803T>C, NP_000020.1:p.Met268Thr, rs17856353, rs3182295, rs386606420, rs4714, rs61617185
A > G
SNP
M268T
No VIP available CA VA
rs72558187 NC_000010.10:g.96701715T>C, NC_000010.11:g.94941958T>C, NG_008385.1:g.8301T>C, NM_000771.3:c.269T>C, NP_000762.2:p.Leu90Pro, XM_005269575.1:c.269T>C, XP_005269632.1:p.Leu90Pro, rs74052158
T > C
SNP
L90P
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 147

Overview

Generic Names
  • irbesartan
Trade Names
  • Avalide
  • Avapro
  • Irbesarran
  • Irbesartan [Usan:Inn]
  • Lrbesartan
Brand Mixture Names
  • Avalide 150/12.5 mg (Hydrochlorothiazide + Irbesartan)
  • Avalide 300/12.5 mg (Hydrochlorothiazide + Irbesartan)

PharmGKB Accession Id

PA450084

Type(s):

Drug

Description

Irbesartan is an angiotensin receptor blocker (ARB) used mainly for the treatment of hypertension. It competes with angiotensin II for binding at the AT1 receptor subtype. Unlike ACE inhibitors, ARBs do not have the adverse effect of dry cough. The use of ARBs is pending revision due to findings from several clinical trials suggesting that this class of drugs may be associated with a small increased risk of cancer.

Source: Drug Bank

Indication

For the treatment of hypertension, as well as diabetic nephropathy with an elevated serum creatinine and proteinuria (>300 mg/day) in patients with type 2 diabetes and hypertension. Irbesartan is also used as a second line agent in the treatment of congestive heart failure.

Source: Drug Bank

Other Vocabularies

Information pulled from DrugBank has not been reviewed by PharmGKB.

Pharmacology, Interactions, and Contraindications

Mechanism of Action

Irbesartan is a nonpeptide tetrazole derivative and an angiotensin II antagonist that selectively blocks the binding of angiotensin II to the AT 1 receptor. In the renin-angiotensin system, angiotensin I is converted by angiotensin-converting enzyme (ACE) to form angiotensin II. Angiotensin II stimulates the adrenal cortex to synthesize and secrete aldosterone, which decreases the excretion of sodium and increases the excretion of potassium. Angiotensin II also acts as a vasoconstrictor in vascular smooth muscle. Irbesartan, by blocking the binding of angiotensin II to the AT 1 receptor, promotes vasodilation and decreases the effects of aldosterone. The negative feedback regulation of angiotensin II on renin secretion is also inhibited, but the resulting rise in plasma renin concentrations and consequent rise in angiotensin II plasma concentrations do not counteract the blood pressure-lowering effect that occurs. The action of ARBs is different from ACE inhibitors, which block the conversion of angiotensin I to angiotensin II, meaning that the production of angiotensin II is not completely inhibited, as the hormone can be formed via other enzymes. Also, unlike ACE inhibitors, irbesartan and other ARBs do not interfere with response to bradykinins and substance P, which allows for the absence of adverse effects that are present in ACE inhibitors (eg. dry cough).

Source: Drug Bank

Pharmacology

Angiotensin II, the principal pressor agent of the renin-angiotensin system, is responsible for effects such as vasoconstriction, stimulation of synthesis and release of aldosterone, cardiac stimulation, and renal reabsorption of sodium. Irbesartan is a specific competitive antagonist of AT 1 receptors with a much greater affinity (more than 8500-fold) for the AT 1 receptor than for the AT 2 receptor and no agonist activity. Irbesartan's inhibition of angiotensin II binding to the AT1 receptor leads to multiple effects including vasodilation, a reduction in the secretion of vasopressin, and reduction in the production and secretion of aldosterone. The resulting effect is a decrease in blood pressure.

Source: Drug Bank

Food Interaction

Take without regard to meals.

Source: Drug Bank

Absorption, Distribution, Metabolism, Elimination & Toxicity

Biotransformation

Hepatic. Irbesartan is metabolized via glucuronide conjugation and oxidation. In vitro studies of irbesartan oxidation by cytochrome P450 isoenzymes indicated irbesartan was oxidized primarily by 2C9; metabolism by 3A4 was negligible.

Source: Drug Bank

Protein Binding

90% bound to serum proteins (primarily albumin and a1-acid glycoprotein) with negligible binding to cellular components of blood.

Source: Drug Bank

Absorption

Rapid and complete with an average absolute bioavailability of 60-80%. Food has no affect on bioavailability.

Source: Drug Bank

Half-Life

11-15 hours

Source: Drug Bank

Toxicity

Hypotension and tachycardia; bradycardia might also occur from overdose, LD 50=mg/kg(orally in rat)

Source: Drug Bank

Clearance

  • 157-176 mL/min

Source: Drug Bank

Route of Elimination

Irbesartan is metabolized via glucuronide conjugation and oxidation. Irbesartan and its metabolites are excreted by both biliary and renal routes. Irbesartan is excreted in the milk of lactating rats.

Source: Drug Bank

Volume of Distribution

  • 53 to 93 L

Source: Drug Bank

Chemical Properties

Chemical Formula

C25H28N6O

Source: Drug Bank

Isomeric SMILES

CCCCC1=NC2(CCCC2)C(=O)N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5

Source: Drug Bank

CCCCC1=NC2(CCCC2)C(=O)N1CC1=CC=C(C=C1)C1=C(C=CC=C1)C1=NNN=N1

Source: Drug Bank

Canonical SMILES

CCCCC1=NC2(CCCC2)C(=O)N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1

Source: Drug Bank

Average Molecular Weight

428.5294

Source: Drug Bank

Monoisotopic Molecular Weight

428.232459548

Source: Drug Bank

SMILES

CCCCC1=NC2(CCCC2)C(=O)N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1

Source: Drug Bank

InChI String

InChI=1S/C25H28N6O/c1-2-3-10-22-26-25(15-6-7-16-25)24(32)31(22)17-18-11-13-19(14-12-18)20-8-4-5-9-21(20)23-27-29-30-28-23/h4-5,8-9,11-14H,2-3,6-7,10,15-17H2,1H3,(H,27,28,29,30)

Source: Drug Bank

Genes that are associated with this drug in PharmGKB's database based on (1) variant annotations, (2) literature review, (3) pathways or (4) information automatically retrieved from DrugBank, depending on the "evidence" and "source" listed below.

Curated Information ?

Drug Targets

Gene Description
AGT (source: Drug Bank)
AGTR1 (source: Drug Bank)
JUN (source: Drug Bank)

Drug Interactions

Interaction Description
amiloride - irbesartan Increased risk of hyperkaliemia (source: Drug Bank)
amiloride - irbesartan Increased risk of hyperkaliemia (source: Drug Bank)
irbesartan - amiloride Increased risk of hyperkaliemia (source: Drug Bank)
irbesartan - amiloride Increased risk of hyperkaliemia (source: Drug Bank)
irbesartan - drospirenone Increased risk of hyperkaliemia (source: Drug Bank)
irbesartan - drospirenone Increased risk of hyperkaliemia (source: Drug Bank)
irbesartan - lithium The ARB increases serum levels of lithium (source: Drug Bank)
irbesartan - lithium The ARB increases serum levels of lithium (source: Drug Bank)
irbesartan - potassium Increased risk of hyperkaliemia (source: Drug Bank)
irbesartan - potassium Increased risk of hyperkaliemia (source: Drug Bank)
irbesartan - spironolactone Increased risk of hyperkaliemia (source: Drug Bank)
irbesartan - spironolactone Increased risk of hyperkaliemia (source: Drug Bank)
irbesartan - triamterene Increased risk of hyperkaliemia (source: Drug Bank)
irbesartan - triamterene Increased risk of hyperkaliemia (source: Drug Bank)
lithium - irbesartan The ARB increases serum levels of lithium (source: Drug Bank)
lithium - irbesartan The ARB increases serum levels of lithium (source: Drug Bank)
trandolapril - irbesartan The angiotensin II receptor blocker, Irbesartan, may increase the adverse effects of Trandolapril. (source: Drug Bank)
treprostinil - irbesartan Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. (source: Drug Bank)
triamterene - irbesartan Increased risk of hyperkaliemia (source: Drug Bank)
triamterene - irbesartan Increased risk of hyperkaliemia (source: Drug Bank)

Curated Information ?

Relationships from National Drug File - Reference Terminology (NDF-RT)

May Treat
Contraindicated With

Publications related to irbesartan: 16

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The renal protective effect of angiotensin receptor blockers depends on intra-individual response variation in multiple risk markers. British journal of clinical pharmacology. 2015. Schievink Bauke, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
The KCNH2 Genetic Polymorphism (1956, C>T) Is a Novel Biomarker That Is Associated with CCB and alpha,beta-ADR Blocker Response in EH Patients in China. PloS one. 2013. He Fazhong, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
CYP2C9*3 and *13 alleles significantly affect the pharmacokinetics of irbesartan in healthy Korean subjects. European journal of clinical pharmacology. 2011. Choi Chang-Ik, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Interactive effect of angiotensin II type 1 receptor (AGT1R) polymorphisms and plasma irbesartan concentration on antihypertensive therapeutic responses to irbesartan. Journal of hypertension. 2011. Jiang Shanqun, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Cytochrome P450 2C9-CYP2C9. Pharmacogenetics and genomics. 2010. Van Booven Derek, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Analytical and bioanalytical chemistry. 2008. Zanger Ulrich M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Angiotensin II blockade and aortic-root dilation in Marfan's syndrome. The New England journal of medicine. 2008. Brooke Benjamin S, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
CYP2C9*3 allelic variant is associated with metabolism of irbesartan in Chinese population. European journal of clinical pharmacology. 2005. Hong Xiumei, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Single nucleotide polymorphisms predict the change in left ventricular mass in response to antihypertensive treatment. Journal of hypertension. 2004. Liljedahl Ulrika, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Single nucleotide polymorphisms in the apolipoprotein B and low density lipoprotein receptor genes affect response to antihypertensive treatment. BMC cardiovascular disorders. 2004. Liljedahl Ulrika, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Gender-specific association between preproendothelin-1 genotype and reduction of systolic blood pressure during antihypertensive treatment--results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA). Clinical cardiology. 2004. Hallberg P, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Angiotensinogen gene polymorphisms: relationship to blood pressure response to antihypertensive treatment. Results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial. American journal of hypertension. 2004. Kurland Lisa, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
The CYP2C9 genotype predicts the blood pressure response to irbesartan: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial. Journal of hypertension. 2002. Hallberg Pär, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics. 2002. Lee Craig R, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Angiotensin converting enzyme gene polymorphism predicts blood pressure response to angiotensin II receptor type 1 antagonist treatment in hypertensive patients. Journal of hypertension. 2001. Kurland L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Role of cytochrome P-4502C9 in irbesartan oxidation by human liver microsomes. Drug metabolism and disposition: the biological fate of chemicals. 1999. Bourrié M, et al. PubMed

LinkOuts

Web Resource:
Wikipedia
National Drug Code Directory:
0087-2771-31
DrugBank:
DB01029
ChEBI:
5959
KEGG Compound:
C07469
KEGG Drug:
D00523
PubChem Compound:
3749
PubChem Substance:
46506575
7847589
IUPHAR Ligand:
589
Drugs Product Database (DPD):
2237924
ChemSpider:
3618
Therapeutic Targets Database:
DAP000364
FDA Drug Label at DailyMed:
b7f1a9ef-c7bb-465c-e4d7-a41395205cad

Clinical Trials

These are trials that mention irbesartan and are related to either pharmacogenetics or pharmacogenomics.

No trials found.

Common Searches

Search PubMed
Search Medline Plus
Search PubChem
Search CTD

Sources for PharmGKB drug information: DrugBank, PubChem.